Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) – Pipeline Review, H2 2018

Global Markets Direct’s, ‘Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) – Pipeline Review, H2 2018’, provides in depth analysis on Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Immunology, Dermatology, Oncology, Gastrointestinal, Musculoskeletal Disorders and Ophthalmology under development targeting Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)

– The report reviews Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects

– The report assesses Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Aclaris Therapeutics Inc

Arrien Pharmaceuticals LLC

Bristol-Myers Squibb Co

Chipscreen Biosciences Ltd

Clevexel Pharma SAS

Daewoong Pharmaceutical Co Ltd

Guangdong Zhongsheng Pharmaceutical Co Ltd

Japan Tobacco Inc

KBP BioSciences Co Ltd

LSK BioPartners Inc

Merck & Co Inc

MYOS RENS Technology Inc

Portola Pharmaceuticals Inc

Sienna Biopharmaceuticals Inc

Simcere Pharmaceutical Group

Theravance Biopharma Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC

2.7.10.2) Overview

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC

2.7.10.2) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC

2.7.10.2) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC

2.7.10.2) Companies Involved in Therapeutics Development

Aclaris Therapeutics Inc

Arrien Pharmaceuticals LLC

Bristol-Myers Squibb Co

Chipscreen Biosciences Ltd

Clevexel Pharma SAS

Daewoong Pharmaceutical Co Ltd

Guangdong Zhongsheng Pharmaceutical Co Ltd

Japan Tobacco Inc

KBP BioSciences Co Ltd

LSK BioPartners Inc

Merck & Co Inc

MYOS RENS Technology Inc

Portola Pharmaceuticals Inc

Sienna Biopharmaceuticals Inc

Simcere Pharmaceutical Group

Theravance Biopharma Inc

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC

2.7.10.2) Drug Profiles

ARN-4079 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATI-1777 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATI-501 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATI-502 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cerdulatinib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CS-510 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CVXL-0074 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

delgocitinib Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWJ-212 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KBP-7536 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LSK-9985 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OST-122 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OST-246 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

peficitinib hydrobromide Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-06651600 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit ITK and JAK3 for Psoriasis and Inflammatory Dermatoses Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit JAK3 for Heart Transplantation Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit JAK3 for Rheumatoid Arthritis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK1 and JAK3 for Inflammation Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK2 and JAK3 for Immunology and Oncology Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK3 for Cachexia, Rheumatoid Arthritis and Sarcopenia Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNA-125 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TD-1473 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tofacitinib citrate Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tofacitinib citrate ER Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC

2.7.10.2) Dormant Products

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC

2.7.10.2) Discontinued Products

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC

2.7.10.2) Product Development Milestones

Featured News & Press Releases

Nov 01, 2018: Portola Pharmaceuticals to present new interim phase 2 results for Cerdulatinib during an oral session at the 60th American Society of Hematology (ASH) Annual Meeting

Oct 22, 2018: Theravance Biopharma reports data from TD-1473 phase 1b four-week study in oral late-breaker presentation at UEG Week 2018

Oct 10, 2018: Theravance Biopharma Announces Data from Phase 1b Study of TD-1473 Selected for Oral Late-Breaker Presentation at UEG Week 2018

Oct 09, 2018: Health Canada approves new indications for Xeljanz in ulcerative colitis (UC) and psoriatic arthritis (PsA)

Sep 25, 2018: Portola Pharmaceuticals receives FDA Orphan Drug Designation for Cerdulatinib, an oral Syk/JAK inhibitor for the treatment of Peripheral T-Cell Lymphoma

Sep 17, 2018: Pfizer reports positive data from Phase lla study for alopecia areata

Sep 05, 2018: Pfizer receives Breakthrough Therapy Designation from FDA for PF-06651600, an oral JAK3 inhibitor, for the treatment of patients with Alopecia Areata

Aug 27, 2018: Sienna Biopharmaceuticals announces results from first-in-human study of SNA-125 in psoriasis and continued progression to phase 2

Aug 01, 2018: Pfizer’s Xeljanz secures marketing authorisation in Europe

Jul 09, 2018: FDA grants Fast Track Designation to Aclaris Therapeutics’ Investigational JAK Inhibitor for the treatment of Alopecia Areata

Jun 28, 2018: XELJANZ (tofacitinib citrate) Receives Marketing Authorization in the European Union for Active Psoriatic Arthritis

Jun 28, 2018: Aclaris Therapeutics Announces Positive Interim Data from Phase 2 study of ATI-502 (a topical JAK inhibitor) in Patients with Alopecia Areata

Jun 26, 2018: Aclaris Therapeutics Announces First Patient Dosed in a Phase 2 Clinical Trial of ATI-501 Oral Suspension in Patients with Alopecia Totalis and Alopecia Universalis

Jun 04, 2018: New Interim Phase 2a Study Results Demonstrate Broad Clinical Activity of Portola Pharmaceuticals’ Oral SYK/JAK Inhibitor Cerdulatinib

Jun 01, 2018: Pfizer Receives Positive CHMP Opinion in European Union for XELJANZ (tofacitinib citrate) for the Treatment of Moderately to Severely Active Ulcerative Colitis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Companies, H2 2018 (Contd..3), H2 2018

Products under Development by Companies, H2 2018 (Contd..4), H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Aclaris Therapeutics Inc, H2 2018

Pipeline by Arrien Pharmaceuticals LLC, H2 2018

Pipeline by Bristol-Myers Squibb Co, H2 2018

Pipeline by Chipscreen Biosciences Ltd, H2 2018

Pipeline by Clevexel Pharma SAS, H2 2018

Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2018

Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H2 2018

Pipeline by Japan Tobacco Inc, H2 2018

Pipeline by KBP BioSciences Co Ltd, H2 2018

Pipeline by LSK BioPartners Inc, H2 2018

Pipeline by Merck & Co Inc, H2 2018

Pipeline by MYOS RENS Technology Inc, H2 2018

Pipeline by Portola Pharmaceuticals Inc, H2 2018

Pipeline by Sienna Biopharmaceuticals Inc, H2 2018

Pipeline by Simcere Pharmaceutical Group, H2 2018

Pipeline by Theravance Biopharma Inc, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Dormant Products, H2 2018 (Contd..2), H2 2018

Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports